Cutaneous T cell lymphoma Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
Conditions: Cutaneous T Cell Lymphoma; Fungoides Mycosis Sezary Syndrome Interventions: Drug: Pembrolizumab; Drug: Mogamulizumab Sponsors: University of Michigan Rogel Cancer Center; Merck Sharp & Dohme LLC; Hoosier Cancer Research Network Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 21, 2023 Category: Research Source Type: clinical trials
